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a  b  s  t  r  a  c  t
Rheumatoid  arthritis  (RA) mainly  affects  various  joints  of the body,  including  the  temporomandibular
joint (TMJ),  and  it involves  an inﬁltration  of autoantibodies  and  inﬂammatory  leukocytes  into  articular
tissues  and  the  synovium.  Initially,  the  synovial  lining  tissue  becomes  engaged  with  several  kinds  of
inﬁltrating  cells,  including  osteoclasts,  macrophages,  lymphocytes,  and plasma  cells.  Eventually,  bone
degradation  occurs.  In  order to elucidate  the  best  therapy  for RA,  a comprehensive  study  of  RA pathogen-





with  an  emphasis  on  the  role  of  sphingosine  1-phosphate  (S1P)/S1P  receptor  1 signaling  which  induces
the  migration  of osteoclast  precursor  cells.  We  describe  that Fas/S1P1 signaling  via NF-B  activation  in
osteoclasts  is  a  key  factor in  TMJ-RA  severity  and  we  discuss  a strategy  for blocking  nuclear  translocation
of  the  p50  NF-B  subunit  as  a potential  therapy  for  attenuating  osteoclastogenesis.
© 2018  The  Authors.  Published  by Elsevier  Ltd on  behalf  of  The  Japanese  Association  for  Dental
Science.  This  is  an  open  access  article  under  the CC BY-NC-ND  license  (http://creativecommons.org/. Introduction
Rheumatoid arthritis (RA) develops when the synovial lining
f joints in the body are inﬁltrated by leukocytes, plasma cells,
ymphocytes, endothelial cells, and activated macrophages that
ediate induction of a chronic inﬂammatory state (Fig. 1) [1,2].
one erosions often accompany the development of an inﬂamma-
ory state in many rheumatic diseases and these destructive bone
esions develop when a break in cortical bone has occurred. Loss of
djacent trabecular and cortical bone structures proximal to a bone
esion generally occur due to osteoclastic bone resorption, a reduc-
ion in articular cartilage, and bone marrow edema [3,4]. The latter
an be detected with magnetic resonance imaging (MRI) [5,6].
In RA, the size and number of erosions that are present in
ffected joints may  be an indicator of the extent of damage that
as occurred. Bone erosions represent the contribution of the bone
arrow compartment to the destruction of bone and the promotion
f cytokines involved in pro-inﬂammation [7,8]. Osteoclasts are
ultinucleated myeloid lineage cells that are able to resorb bone,
nd these cells are essential for the remodeling and regeneration of
one. In degenerative diseases such as arthritis, osteoporosis, and
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cancer bone metastasis, the presence of an excessive number of
osteoclasts has been found to contribute to bone destruction [9].
Receptor activator of NF-B ligand (RANKL) and macrophage
colony-stimulating factor (M-CSF) stimulate the generation of
osteoclast cells [10–13]. In response to sphingosine 1-phosphate
(S1P) signaling, osteoclasts then attach to regions of bone under-
going resorption [14]. In RA when S1P is expressed at higher levels,
sphingosine kinase (Sphk) 1 is also present at higher levels and this
leads to resistance to Fas-mediated death signaling (Fig. 2) [15,16].
The activity and number of osteoclasts are modulated by rates of
cell death and cell differentiation [17].
Communication between osteoclasts and osteoblasts or T cells
is also mediated by RANKL and S1P receptor 1 (S1P1), and this
signaling promotes cell regulation, proliferation, migration, apo-
ptosis, expression of inﬂammatory genes [18–20], chemotaxis [21],
and differentiation [22,23]. Events downstream of RANKL binding
to osteoclasts involves the activation of various signaling path-
ways, including nuclear factor of activated T cells cytoplasmic 1
(NFATc1), Akt/PKB, NF-B, JNK, p38, and ERK, to induce the differ-
entiation, activity, and survival of osteoclasts [14,24]. In addition,
RANKL binding of osteoclast progenitor cells leads to upregula-
tion of Fas expression via NF-B, thereby resulting in osteoclast
cells being targets of Fas-stimulated apoptosis [25]. To promote cell
death, Fas-stimulated apoptosis in osteoclasts involving the release
ociation for Dental Science. This is an open access article under the CC BY-NC-ND
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fig. 1. Bone destruction associated with TMJ-RA. RANKL is produced by T cells an
he  local destruction of cartilage and eventually severe subchondral trabecular bone
ells  (monocytes) concomitant with a decrease in the recruitment and differentiati
f cytochrome c from mitochondria and activation of both caspase
 and caspase 9 [17].
To date, the predominant strategies for decreasing bone
esorption include the addition of estrogen, tamoxifen, or cer-
ain bisphosphonates to accelerate the death rate of osteoclasts
r decrease osteoclast formation [17,26–30]. In this review, we
iscuss our ﬁndings that osteoclast activity-dependent Fas/S1P1
ignaling via activation of NF-B mediates the development of RA
nd bone resorption in the TMJ. In addition, a prospective therapeu-
ic intervention involving administration of SN50 to block signaling
y p50 NF-B to attenuate osteoclastogenesis in the pathogene-
is of temporomandibular joint rheumatoid arthritis (TMJ-RA) is
iscussed.
. TMJ-RA
The TMJ  is needed for sliding and hinge movements of the
aw. Consequently, it is the most frequently used joint in the body
31]. The TMJ  is composed of an articular disc and the mandibular
ondyle which provide upper and lower articular cavities between
he condyle and the glenoid fossa [32]. Unlike other synovial joints,
he condyle of the mandible of the TMJ  produces less type I collagen
33], its superﬁcial layer does not produce type II collagen, and its
rticular surfaces consist of ﬁbrous tissue rather than hyaline carti-
age [34]. In addition, mandibular condyle cartilage originates from
ranial neural crest cells and is considered a secondary cartilage of
he chondroskeleton [35].
Clinically, the TMJ  is involved in 4–80% of RA cases [36–38].
his wide range is due on the different examinations performed,
he different selection of the patient populations and age distribu-
ion, the duration of the RA occurs, the different diagnostic criteria
or classifying joint involvement, and the imaging techniques usedmed synovium (synovitis) tissue. The presence of this cytokine in the TMJ leads to
as a result of the recruitment and enhanced differentiation of osteoclast progenitor
steoblast progenitor cells and MSCs.
[5,37–43]. However, more than 50% of patients with RA complaints
about TMJ  discomfort [36,44,45].
Manifestation of RA in the TMJ  can include swelling, pain,
impaired movement, and crepitation. These characteristics are sim-
ilar to the manifestations of RA in other joints, and these symptoms
usually correlate well with radiographic change observed in joints.
Speciﬁcally in the TMJ, radiographic changes can include erosion,
the presence of a subcortical cyst, and a gradual decrease in joint
space due to granulation, deossiﬁcation, pencil head, or spiked
deformity of the condylar head [41,44].
Several studies were found in TMJ-RA. Proteoglycan-induced
arthritis mice showed a degradation of cartilage matrix in TMJ
due to the effects of the cytokines from the inﬂamed joints [46].
The ratio of RANKL and OPG was signiﬁcantly increased in TMJ  of
collagen-induced acetate rats [47]. The pathway of TMJ  involve-
ment in human RA was  found to be the same as in other joints based
on the analysis of histological ﬁndings [48]. However, it should be
emphasized that due to the originates difference of the cartilage of
TMJ  and other joints [35], the pathogenesis of RA in TMJ may  differ
from the other joints.
Therefore, the histomorphology and the comprehensive analy-
sis of TMJ-RA pathogenesis need to be completed although clinical
ﬁndings in TMJ-RA are similar to RA in other joints [41]. Especially
for the dentist, the difﬁculties associated with diagnosing TMJ-RA
patients [49] posing challenges to diagnose and recover the effects
of TMJ-RA.
3. Fas-deﬁciency in RA pathogenesisFas antigen is expressed in various tissues, including the thymus.
Fas antigen also shares structural homology with many cell-surface
receptors (e.g., tumor necrosis factor (TNF) receptors) and has been
shown to mediate apoptosis [50]. In human RA, FLICE-inhibitory
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if  RANK to RANKL, IB proteins are rapidly phosphorylated. As a result, the p50 a
ene  transcription. Overexpression of Sphk1 and S1P1 accelerates the migration of 
urvival and massive bone destruction.
rotein (FLIP) an antiapoptotic protein, has been detected in syn-
vial tissues and ﬁbroblast-like synoviocytes (FLS) culture. It has
een reported that FLS of RA is sensitized to promote Fas mediated-
poptosis by the down-regulation of FLIP [51].
In mice, the Fas antigen gene maps to chromosome 19 and mice
hat carry a lymphoproliferation mutation (MRL/lpr mice) have
een found to have defects in the Fas antigen gene [52,53]. An
berrant transcription factor in MRL/lpr mice causes premature ter-
ination of Fas transcription, and this results in aberrant splicing of
as mRNA (Fig. 2) [54]. The clinical symptoms exhibited by MRL/lpr
ice include hypergammablobulinaemia, production of anti-DNA
ntibodies, rheumatoid factor (RF), arthritis, and glomerulonephri-
is. Moreover, the latter closely resembles human autoimmune
ystemic lupus erythematosus (SLE) [55].
MRL/lpr mice are suitable as a model to study an immune
omplex disease, to determine the etiology, and to evaluate the
herapies. Several studies were done using MRL/lpr mice, such
s the effect of the radiation therapy to ameliorate the autoim-
une disease [56], the therapeutic effects of Artemisinin analog
M934 to ameliorate lupus syndromes [57], allergic inﬂammation
n blepharitis [58], the analysis pathogenesis of Graft-versus-host
isease (GVHD)-like wasting syndrome by defects in Fas-mediated
ymphocyte apoptosis [59], and histopathological analysis of spon-
aneous arthritis [60,61].
The pathogenesis of RA in MRL/lpr mice particularly involves
nteractions between osteoclast cells and immune cells (e.g., acti-1
5 subunits of NF-B are able to translocate to the nucleus, bind DNA, and activate
last progenitor cells, while defects in Fas mitigate apoptosis to promote osteoclast
vated dendritic cells (DCs) with peripheral T cells) via RANKL
activation. Thus, a possible therapeutic treatment for lymphoprolif-
erative and autoimmune arthritis has been tested in MRL/lpr mice
with induction of Fas-independent apoptosis of CD4+ T cells via
TRAIL/TRAIL-R2 which was  achieved by performing multiple trans-
fers of activated and Fas-deﬁcient DCs [62,63]. It has been reported
that osteoprotegerin (OPG) induces apoptosis in osteoclast and
osteoclast precursor via Fas/FasL pathway. OPG has been shown
to trigger the increase of Bax/Bcl-2 ratio and the level of activated
cleaved-caspase 9 and caspase 3 in dose-dependent manner [64].
When staining for tartrate-resistant acid phosphatase (TRAP)
was performed in long bones and the TMJs of MRL/lpr mice and
control mice, the former contained a greater number of osteoclasts.
This observation suggests that mutation of Fas leads to prolonged
survival of osteoclasts (Fig. 2) [17,65]. Correspondingly, defects in
Fas have been associated with a greater number of osteoclasts and
subsequent reductions in bone mineral density, bone volume, and
trabecular thickness [17].
4. The role of S1P/S1P1 signaling in osteoclasts under RA
conditionsS1P, a cell-derived lysophospholipid growth factor [66], is the
ﬁnal metabolite of the sphingolipid pathway and it is generated
from Sphk and S1P lyase [67]. S1P binds G protein-coupled recep-
tors (GPCRs) at the cell surface, particularly the S1P1–5 receptors
I.R. Hutami et al. / Japanese Dental Science Review 55 (2019) 12–19 15

































Snduce  intracellular signaling that leads to the activation of kinases that phosphor
ocalizes to the cell membrane from the cytosol to convert sphingosine to S1P via p
athway, while S1P2 and S1P3 are linked to G12/13 and activate the Rho signaling p
Fig. 3) [68], to mediate a wide variety of essential cellular pro-
esses: cell differentiation, survival, proliferation, migration, and
nvasion, as well as angiogenesis and trafﬁcking of immune cells
69–72]. While S1P1–3 are widely expressed in various tissues,
xpression of S1P4 and S1P5 is restricted to immune cells and cells
f the central nervous system [73,74].
Potential roles for S1P in angiogenesis, cancer, and autoimmune
iseases such as RA have been reported [73]. In RA synoviocytes,
1P has been shown to enhance expression of prostaglandin E2
PGE2) and cyclooxygenase-2 (COX-2) in response to the pro-
nﬂammatory cytokines, TNF- and interleukin (IL)-1 [18]. These
ytokines production induce expression of matrix metallopro-
einases (MMPs) and activate osteoclasts, thereby resulting in bone
esorption and soft tissue damage [75]. Osteoclasts themselves also
xpress S1P, and this molecule stimulates the migration of both
steoblasts and mesenchymal stem cells (MSCs). Accordingly, S1P
hat derives from osteoclasts may  attract osteoblasts to areas of
one resorption as one of the ﬁrst steps in the process of replacing
one that is lost in a damaged area [76].
S1P signaling via S1P1 regulates T cell development and
nhances synoviocyte proliferation, inﬂammatory cytokine expres-
ion, and osteoclastogenesis in bone homeostasis [23,77–79].
eanwhile, expression of Sphk1 has been shown to be higher in
steoclasts that have cathepsin K deleted. These osteoblasts also
xhibited a higher RANKL/OPG ratio which corresponded with a
reater number of osteoclasts present [80].
Differentiation and maturation of osteoclasts require signaling
ia Sphk1/S1P/S1P3 as previously demonstrated in assays of Runx2
xpression and alkaline phosphatase activity [81]. Transforming
rowth factor (TGF)-/Smad3 signaling has also been shown to
ffect cartilage homeostasis by inﬂuencing S1P/S1P receptor sig-
aling and chondrocyte migration. Correspondingly, in mice with
mad3-deﬁcient chondrocytes, only the Sphk1/S1P/S1P3 signalingphk1. S1P is subsequently generated following phosphorylation of Sphk, and S1P
orylation events. S1P1 is linked to Gi and is a potent activator of the Rac signaling
ay.
axis was found to play an important role in degradation of the
mandibular condylar [82].
The S1P/S1P1 signaling axis controls the migration of osteoclast
precursor cells [21–23,83] from bone tissues into blood circula-
tion [21] and it may  also induce synovial hyperplasia in RA. RANKL
stimulation has been found to decrease expression of S1P1 in an
NF-B-dependent manner (Fig. 2) yet not in a NFATc1-dependent
manner [21,23]. Furthermore, RANKL expression during osteoclas-
togenesis that is induced by the Sphk1/S1P1 signaling axis is the
result of interactions between macrophages and bone marrow
derived stromal cells (BMSCs) [84].
However, in our recent study, only expression of Sphk1 and S1P1
in MRL/lpr mice increased in the mandibular condyle, and these
increases were accompanied by an increase in Rac1 activity (Fig. 3)
[21,65]. Correspondingly, treatment with a S1P1 agonist led to a
signiﬁcant reduction in inﬂammation and joint destruction, consis-
tent with the predicted actions of the agonist in retaining osteoclast
precursor cells [85]. Taken together, these ﬁndings suggest that tar-
geting the S1P/S1P1 signaling axis represents a potential treatment
for RA [18].
During the development of RA, expression of S1P and S1P1–5
by osteoclasts [65], osteoblasts [81], chondrocytes [82], and MSCs
[76,86] is considered to be essential for modulating cell migration,
cell survival, and cytokine or chemokine production during bone
formation (Fig. 1) [65,87]. Therefore, it will be important for future
studies to evaluate the role of the S1P/S1P receptor system among
the cell-cell interactions that mediate bone homeostasis in TMJ-RA
pathogenesis (Fig. 4).5. Role of the NF-B in osteoclasts
NF-B is an inducible transcription factor that binds a partic-
ular DNA sequence that is present in a large number of target
16 I.R. Hutami et al. / Japanese Dental Science Review 55 (2019) 12–19
Fig. 4. Schematic representation of the bone remodeling process. When Fas is defective, a greater amount of S1P is released by osteoclasts (grey arrows) and this leads
t r stim










































so  increased production of RANKL by osteoblasts (black arrow). As a result, greate
ifferentiation of osteoclasts is enhanced. S1P that is produced by osteoclasts serve
ost  bone. An overall increase in the level of S1P then stimulates bone formation.
enes, especially genes that contribute to immune responses and
athogen defense. In autoimmune diseases, such as RA, NF-B has
n essential role in the differentiation, survival, activation, and
evelopment of osteoclasts [88–90].
Two important proteins in osteoclastogenesis are RANK and its
igand, RANKL (also referred to as TNFRSF11A and TRANCE, respec-
ively). In addition to activating mature osteoclasts, RANKL can
ombine with M-CSF to regulate osteoclast differentiation from
onocyte/macrophage precursor cells [14,89,91]. Numerous stud-
es have demonstrated that differentiation of osteoclast precursor
ells requires induction of NF-B activity by RANKL [88,92,93],
hile activation of macrophages and osteoclasts requires NF-B
ignaling as well [88,94].
Phosphorylation of the p50-Rel A dimer, the most common
orm of NF-B, leads to ubiquitination of IB proteins (Fig. 2).
oly-ubiquitination of IB proteins identiﬁes them for rapid degra-
ation by 26S proteasomes, thereby allowing NF-B dimers to
ndergo nuclear translocation and activate the transcription of var-
ous target genes [95]. However, prior to their degradation, the
hosphorylation of IB proteins by the IB kinase (IKK) complex
acilitates NF-B activation. The IKK complex consists of a reg-
latory component, IKK or NF-B essential modulator (NEMO),
nd catalytic subunits (IKK and IKK) [95–98]. In MRL/lpr mice,
hosphorylation of IB, an endogenous inhibitory molecule of
F-B activation and nuclear translocation of the p50 and p65 sub-
nits of NF-B, is signiﬁcantly enhanced compared with control
ice [65,99]. These results suggest that osteoclast activation which
ccurs with RA involves a role for the classical pathway of NF-B
ctivation (Fig. 2).
Correspondingly, in both in vivo and in vitro studies a cell-
ermeable peptide spanning a NEMO-binding domain has been
hown to inhibit osteoclastogenesis and activation of NF-B
nduced by RANKL [88]. Therefore, it is proposed that a potential
trategy for preventing osteoclastogenesis and effectively treating
he inﬂammation associated with bone resorption is to selectively
nhibit NF-B in osteoclasts [65,88].
. Blocking nuclear translocation of NF-B in osteoclasts as
herapeutic target of RA
Different strategies have been proposed and tested to inhibit
he activation or function of NF-B. One approach has employed
ecoy NF-B sites or their analogs to interfere with the binding
f NF-B to DNA [100]. However, such molecules are polar and
ather large, thereby potentially hindering their uptake and cellular
ioavailability [96]. Conversely, considering the large interaction
urface between NF-B and DNA, it may  be difﬁcult for non-polarulation of osteoblasts and the migration of osteoclast precursor cells occurs, and
cruit osteoblasts to bone resorption sites as an initial step in the process to replace
molecules that are small in size to speciﬁcally disrupt the binding of
NF-B to DNA [96]. A similar argument could be made for molecules
designed to inhibit NF-B protein dimerization [96,101].
Alternatively, it has been proposed that small peptides that can
readily cross the cell membrane could inhibit the activation of NF-
B by blocking translocation of the NF-B complex to the nucleus.
This approach was tested by generating a synthetic peptide that
contains the nuclear localization sequence of the p50 NF-B subunit
and a hydrophobic region to facilitate translocation across a cell
membrane. This peptide, named SN50, was  shown to competitively
inhibit the nuclear translocation of NF-B (Fig. 2) [96,100,102].
Moreover, both in vivo and in vitro, SN50 was  found to effectively
inhibit TNF- and lipopolysaccharide (LPS)-induced inﬂammatory
responses [102]. SN50 has also been shown to block the translo-
cation of many other transcriptional factors to the nucleus, and to
abrogate activation of caspase-3 [96,100,103,104]. In mice, admin-
istration of SN50 effectively suppressed NF-B activation that was
dependent on TNF-/JNK signaling [105], as well as MMP  produc-
tion in alveolar macrophages [106]. Furthermore, in resting normal
human peripheral blood derived T cells, the addition of SN50 abol-
ished osteoclast differentiation and induced apoptosis [107,108].
Based on the results presented here, blocking nuclear transloca-
tion of the p50 NF-B subunit appears to be an effective approach
for attenuating the number of osteoclasts present and reducing
expression of Sphk1 and S1P1. In particular, it has recently been
demonstrated that SN50 targeting of p50 NF-B translocation to
the nuclei of bone marrow macrophages (BMMs) in RA model of
MRL/lpr mice inhibits RANKL-induced osteoclastogenesis (Fig. 2)
[65].
Subchondral trabecular bone loss in the mandibular condyle
was also ameliorated, and this was accompanied by lower expres-
sion levels of the osteoclast marker, TRAP, as well as cathepsin
K, vascular endothelial growth factor (VEGF), MMP-9, and RANKL.
Moreover, treatment with SN50 increased expression of OPG and
reduced Sphk1 expression and S1P1 signaling [65]. Taken together,
these ﬁndings suggest that SN50 is an effective inhibitor of osteo-
clastogenesis and the preceding migration of osteoclast precursor
cells.
7. Conclusions
Osteoclcastogenesis is regulated by multiple signal transduc-
tion pathways. To maintain bone homeostasis, osteoclast cells must
achieve a balance regulation of formation, function, and trafﬁcking
of its precursors. Here, we proposed a model in which crosstalk
between Fas and S1P/S1P1 signaling occurs in osteoclast precursor
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aling affects the migratory behavior of osteoclast precursor cells
hich is crucial for the pathogenesis of RA.
The TMJ  has special characteristics that distinguish it from other
oints in the human body. Correspondingly, disorders, symptoms,
nd disease distribution involving the TMJ  are unlike those of other
oint disorders. As a result, treatments speciﬁc for the TMJ  may be
eeded. However, given that the TMJ  is part of a dynamic tissue
hat undergoes constant remodeling as a result of bone resorp-
ion and bone formation processes that are mediated by osteoclasts
nd osteoblasts, respectively, continued efforts are needed to bet-
er understand RA pathogenesis for the identiﬁcation of effective
ew therapies.
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